Cas:90267-03-1 1-Bromo-3,5-diethylbenzene manufacturer & supplier

Chemical Name:1-Bromo-3,5-diethylbenzene

CAS.NO:90267-03-1

Synonyms:1-Bromo-3,5-diethylbenzene;Benzene, 1-bromo-3,5-diethyl-

Molecular Formula:C₁₀H₁₃Br

Molecular Weight:213.114

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:247.0±9.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.532

PSA:

Exact Mass:212.020050

LogP:4.97

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-Bromo-3,5-diethylbenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzene, 1-bromo-3,5-diethyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Bromo-3,5-diethylbenzene Use and application,1-Bromo-3,5-diethylbenzene technical grade,usp/ep/jp grade.

Related News: The new restrictions on foreign nationals begin on February 3, Prime Minister Jacinda Ardern announced in a press release Sunday. 1-Bromo-3,5-diethylbenzene manufacturer The Philippines, the United States and Australia have expanded travel restrictions, temporarily barring noncitizens who have recently traveled to China. 1-Bromo-3,5-diethylbenzene supplier In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. 1-Bromo-3,5-diethylbenzene vendor In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. 1-Bromo-3,5-diethylbenzene factory In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday.